Published in Br J Clin Pharmacol on September 01, 2012
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring. Br J Clin Pharmacol (2013) 1.06
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol (2014) 0.89
The discovery of dabigatran etexilate. Front Pharmacol (2013) 0.86
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz (2015) 0.79
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br J Pharmacol (2014) 0.78
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Response to the letter by Dr Chin and co-workers. Br J Clin Pharmacol (2013) 0.75
Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D (2014) 0.75
Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein. Eur J Clin Pharmacol (2016) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
The analysis of multiple endpoints in clinical trials. Biometrics (1987) 3.83
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet (2003) 3.37
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol (2007) 3.09
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet (2008) 3.00
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos (2007) 2.47
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet (2008) 1.71
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther (1996) 1.39
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol (2003) 1.21
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost (2010) 1.00
Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol (1999) 0.92
Vitamin K antagonists--current concepts and challenges. Thromb Res (2011) 0.91
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs (2009) 0.86
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol (2010) 0.84
Practical aspects of the oral new anticoagulants. Am J Hematol (2011) 0.81
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 6.36
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Endoscopic ultrasound as a first test for diagnosis and staging of lung cancer: a prospective study. Am J Respir Crit Care Med (2006) 3.35
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation (2012) 2.74
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J (2009) 2.61
A data model and database for high-resolution pathology analytical image informatics. J Pathol Inform (2011) 2.54
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med (2015) 2.44
GridIMAGE: a novel use of grid computing to support interactive human and computer-assisted detection decision support. J Digit Imaging (2007) 2.21
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol (2007) 1.93
Rb is critical in a mammalian tissue stem cell population. Genes Dev (2007) 1.92
Informatics in radiology: GridCAD: grid-based computer-aided detection system. Radiographics (2007) 1.84
Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci (2006) 1.70
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng (2011) 1.63
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail (2013) 1.50
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score. Circ J (2015) 1.41
ImageMiner: a software system for comparative analysis of tissue microarrays using content-based image retrieval, high-performance computing, and grid technology. J Am Med Inform Assoc (2011) 1.40
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 1.38
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Sharing data and analytical resources securely in a biomedical research Grid environment. J Am Med Inform Assoc (2008) 1.36
e-Science, caGrid, and Translational Biomedical Research. Computer (Long Beach Calif) (2008) 1.32
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation (2014) 1.30
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology (2013) 1.28
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol (2013) 1.24
Optimizing diagnosis and management of nocardia keratitis, scleritis, and endophthalmitis: 11-year microbial and clinical overview. Ophthalmology (2011) 1.22
Behavioral manifestations of sturge-weber syndrome: a case report. Prim Care Companion J Clin Psychiatry (2006) 1.22
Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest (2008) 1.19
The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res (2013) 1.16
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology (2013) 1.14
Antibiotic prescribing in outpatients: Hospital and seasonal variations in Ujjain, India. Scand J Infect Dis (2011) 1.14
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol (2011) 1.11
Managing and Querying Image Annotation and Markup in XML. Proc SPIE Int Soc Opt Eng (2010) 1.10
Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res (2010) 1.09
Psychogenic polydipsia. Indian J Psychiatry (2011) 1.08
Protocol modifications for CT perfusion (CTp) examinations of abdomen-pelvic tumors: impact on radiation dose and data processing time. Eur Radiol (2011) 1.05
Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med (Berl) (2011) 1.05
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther (2013) 1.04
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. Circ J (2011) 1.02
A roadmap for caGrid, an enterprise Grid architecture for biomedical research. Stud Health Technol Inform (2008) 1.01
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther (2006) 1.01
Surveillance of antibiotic consumption using the "focus of infection" approach in 2 hospitals in Ujjain, India. PLoS One (2012) 1.00
Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol (2002) 0.99
Acute pancreatitis after EUS-guided FNA of solid pancreatic masses: a pooled analysis from EUS centers in the United States. Gastrointest Endosc (2004) 0.98
Enhancement of Cellulase Activity from a New Strain of Bacillus subtilis by Medium Optimization and Analysis with Various Cellulosic Substrates. Enzyme Res (2011) 0.97
HPC AND GRID COMPUTING FOR INTEGRATIVE BIOMEDICAL RESEARCH. Int J High Perform Comput Appl (2009) 0.97
Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother (2013) 0.97
Inflammasome-mediated IL-1β production in humans with cystic fibrosis. PLoS One (2012) 0.95
Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol (2011) 0.95
Intestinal expression of genes involved in iron absorption in humans. Am J Physiol Gastrointest Liver Physiol (2002) 0.93
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients. Clin Ophthalmol (2010) 0.92
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother (2013) 0.91
Estimation of salivary and tongue coating pH on chewing household herbal leaves: A randomized controlled trial. Anc Sci Life (2012) 0.91
Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2009) 0.91
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment. Eur J Pharmacol (2011) 0.90
Percutaneous transcatheter arterial embolization of inferior pancreatico-duodenal artery aneurysms associated with celiac artery stenosis or occlusion. Catheter Cardiovasc Interv (2010) 0.89
Levetiracetam-induced acute psychotic episode. Innov Clin Neurosci (2012) 0.89
Challenges in containing the burden of hepatitis B infection in dialysis and transplant patients in India. Nephrology (Carlton) (2011) 0.89
Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol (2007) 0.88
Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol (2009) 0.88
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther (2009) 0.86
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer (2013) 0.86
An acetazolamide based multimodal analgesic approach versus conventional pain management in patients undergoing laparoscopic living donor nephrectomy. Indian J Anaesth (2009) 0.85
Isolated renal allograft arterial mucormycosis: an extremely rare complication. Nephrol Dial Transplant (2003) 0.84
A global assessment of climate-water quality relationships in large rivers: an elasticity perspective. Sci Total Environ (2013) 0.84
Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb Haemost (2011) 0.83
Ionizing radiation induces tumor cell lysyl oxidase secretion. BMC Cancer (2014) 0.83
Translational Research Design Templates, Grid Computing, and HPC. IPDPS (2008) 0.83
Reply: regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol (2014) 0.83
An analysis of postoperative complications and efficacy of 3-D miniplates in fixation of mandibular fractures. Dent Res J (Isfahan) (2012) 0.83
Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine. Psychooncology (2012) 0.83
Versatility of Titanium 3D Plate in Comparison with Conventional Titanium Miniplate Fixation for the Management of Mandibular Fracture. J Maxillofac Oral Surg (2012) 0.83
Acute psychosis with Coricidin cold medicine. Ann Pharmacother (2005) 0.82
Antibiotic prescribing in medical intensive care units--a comparison between two private sector hospitals in Central India. Infect Dis (Lond) (2015) 0.82
Differential effects of nicotine on retinal and vascular cells in vitro. Toxicology (2009) 0.82
Natural killer T cells constitutively expressing the interleukin-2 receptor α chain early in life are primed to respond to lower antigenic stimulation. Immunology (2010) 0.81
Arterial interventions for renovascular hypertension. Semin Intervent Radiol (2009) 0.81
Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab (2002) 0.80
Psychosis in a patient with Danon cardiomyopathy. Gen Hosp Psychiatry (2010) 0.80
An imaging workflow for characterizing phenotypical change in large histological mouse model datasets. J Biomed Inform (2008) 0.80